1	Risk of heart disease following breast cancer: results from a population-based cohort
2	study
3	Haomin Yang, PhD ^{1,2} , Nirmala Bhoo-Pathy, PhD ³ , Judith S. Brand, PhD ⁴ , Elham Hedayati,
4	PhD ⁵ , Felix Grassmann, PhD ^{2,6} , Erwei Zeng, MSc ² , Jonas Bergh, PhD ^{5,7,8} , Weiwei Bian,
5	MSc ² , Jonas F. Ludvigsson, PhD ^{2,9} , Per Hall, PhD ^{2,10} , Kamila Czene, PhD ²
6	Author affiliations:
7	1. Department of Epidemiology and Health Statistics, School of Public Health, Fujian
8	Medical University, 350122, Fuzhou, China
9	2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels
10	Väg 12A, 171 77 Stockholm, Sweden.
11	3. Centre for Epidemiology and Evidence-Based Practice, Faculty of Medicine, University
12	of Malaya, 50603 Lembah Pantai, Kuala Lumpur, Malaysia.
13	4. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro
14	University, 70185, Örebro, Sweden.
15	5. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
16	6. Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
17	7. Breast Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
18	8. Karolinska Comprehensive Cancer Center, Stockholm, Sweden
19	9. Department of Pediatrics, Örebro University Hospital, 70185 Örebro, Sweden
20	10. Department of Oncology, South General Hospital, 118 83 Stockholm, Sweden
21	*Corresponding author:
22	Haomin Yang, PhD. Email: haomin.yang@ki.se; Phone: 0086-13581540402; Fax: 0086-591-
23	22862510. Department of Epidemiology and Health Statistics, School of Public Health, Fujian
24	Medical University, Xuefu North Road 1, University Town, Fuzhou, China.
25	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 26 Tables: 3; Figures: 1; Supplementary Tables: 4
- 27 **References:** 44
- 28 Word count:2744
- 29 Running title: Risk of heart diseases following breast cancer

30

31 LIST OF ABBREVIATIONS

- 32 ICD: International Classification of Diseases
- 33 CI: confidence intervals
- 34 HR: hazard ratio
- 35 CCI: Charlson Comorbidity Index

37 ABSTRACT

38 BACKGROUND: There is a rising concern about treatment-associated cardiotoxicities in breast39 cancer patients.

40 **OBJECTIVES:** This study aimed to determine the time- and treatment-specific incidence of 41 arrhythmia, heart failure and ischemic heart disease in women diagnosed with breast cancer.

METHODS: A register-based matched cohort study was conducted including 8338 breast cancer patients diagnosed from 2001-2008 in the Stockholm-Gotland region and followed-up until 2017. Overall and time dependent risks of arrhythmia, ischemic heart disease and heart failure in breast cancer patients were assessed using flexible parametric models as compared to matched controls from general population. Treatment-specific effects were estimated in breast cancer patients using Cox model.

RESULTS: During a median follow-up of 10.8 years, the hazard ratios for arrhythmia, heart failure 48 and ischemic heart disease, were 1.27 (95% CI = 1.18-1.37), 1.38 (95% CI = 1.23-1.55), and 0.93 49 (95% CI = 0.84-1.03), respectively. Time-dependent analyses revealed long-term increased risks of 50 arrhythmia, and heart failure in breast cancer patients compared to matched controls. The risk of 51 ischemic heart disease was only elevated in the first year after cancer diagnosis. Trastuzumab and 52 anthracyclines were associated with increased risk of heart failure. Aromatase inhibitors, but not 53 tamoxifen, were associated with risk of ischemic heart disease. No increased risk of heart disease 54 was identified following loco-regional radiotherapy. 55

56 **CONCLUSIONS:** Administration of systemic adjuvant therapies appear to be associated with 57 increased risks of heart disease. The risk estimates observed in this study may serve as reference to 58 aid adjuvant therapy decision-making and patient counseling in oncology practices.

60 INTRODUCTION

61 The use of adjuvant systemic therapies at least halves the risk of dving from breast cancer (Early Breast Cancer Trialists' Collaborative, 2005, 2012; Early Breast Cancer Trialists' 62 Collaborative et al., 2015; Goldvaser et al., 2019; Gray et al., 2019). Nowadays, 80% of the 63 breast cancer patients survive for at least 10 years and many will become long-term survivors 64 65 (Colzani et al., 2011a). There are, however, concerns about therapy associated late adverse 66 health effects, including cardiovascular events (Khouri et al., 2012). Use of common (neo-) adjuvant therapies for breast cancer have been associated with an increased risk of heart 67 diseases including heart failure, arrhythmias and ischemic heart disease (Darby et al., 2013; 68 69 Doyle, Neugut, Jacobson, Grann, & Hershman, 2005; Harris et al., 2006; Hooning et al., 2007; Pinder, Duan, Goodwin, Hortobagyi, & Giordano, 2007; C. Taylor et al., 2017; Yeh & 70 71 Bickford, 2009). However, this evidence mostly comes from studies focusing on specific 72 subgroups of patients based on age, cancer stage or treatment regimen.

Although the benefits of radiotherapy far outweigh the risk of heart diseases, some studies 73 74 have found increased incidence of and mortality due to heart disease in women subjected to modern doses of adjuvant radiotherapy (Darby et al., 2013; C. Taylor et al., 2017). Knowledge 75 on cardiotoxic effects of anthracycline-based chemotherapy regimens have led to lowering of 76 77 doses and less use of bolus injections to reduce peak concentrations of anthracyclines (Foukakis et al., 2016), but it is estimated that the risk of heart failure associated with anthracyclines 78 remains increased for standard low-dose group as compared to non-users (Chung et al., 2020). 79 80 While trastuzumab has been shown to reduce the risk of breast cancer mortality at 11 years of follow-up (Cameron et al., 2017), evidence on its cardiotoxicity is conflicting (Bowles et al., 81 2012; Papakonstantinou et al., 2020). In addition, recent evidence suggests that use of aromatase 82 inhibitors in women with hormone receptor positive breast cancer may increase the risk of heart 83

failure, compared to tamoxifen (Khosrow-Khavar, Filion, Bouganim, Suissa, & Azoulay,
2020).

Risk assessment of immediate and later occurring heart disease events following breast cancer is important for the planning of cardiac surveillance programs and possible prophylactic pharmacotherapy. Here, we report the risks of heart diseases in in a cohort representative of the general breast cancer population with long-term follow-up. We specifically aimed to assess risks of heart diseases by time since diagnosis, and according to adjuvant treatments.

91 Materials and Methods

92 Breast cancer cohort

93 This study took advantage of the Stockholm-Gotland Breast Cancer Register comprising all 94 women diagnosed with primary invasive breast cancer between 2001 and 2008 in the Stockholm-Gotland region. The Stockholm-Gotland Breast Cancer Register has about 99% completeness and 95 provides detailed information on tumor and treatment characteristics, as well as routine follow-up 96 on locoregional recurrences and distant metastases (Colzani et al., 2011b; Wigertz et al., 2012). We 97 included all patients diagnosed with non-metastatic disease (stages I-III) at age 25 to 75 years (N = 98 8338). To compare the risk of heart diseases after breast cancer, we randomly sampled up to 10 99 women from the general female population in Stockholm-Gotland region matched on year of birth 100 and whether they had history of the three heart diseases (Supplementary Figure 1). We performed 101 the matching procedure for these three heart diseases separately. Each reference individual was alive 102 and free of breast cancer on the date of the matched patient's diagnosis of breast cancer (the index 103 date). 104

The matched cohort was linked through the unique personal identity number to the Swedish Cancer Register, Patient Register, Cause of Death Register and Migration Register, and follow-up started from the index date until the date of heart disease diagnosis, emigration, death, breast cancer relapse or end of follow-up (31 December 2017), whichever occurred first. We also performed

linkage with the Prescribed Drug Register which contains data on all drugs dispensed from Swedish
pharmacies from July 2005 onward to validate the use of hormone therapy. Detailed description of
the breast cancer cohort can be found elsewhere (Holm et al., 2016).

112 The study was approved by the Regional Ethical Review Board in Stockholm.

113 <u>Heart diseases</u>

We identified the following heart diseases according to relevant ICD (International 114 Classification of Disease) codes in the Swedish Patient Register and the Cause of Death 115 116 Register (Supplementary Table 1): heart failure (ICD-10: I50, ICD-9: 428A, 428B, 428X), arrhythmias (ICD-10: I47-I49, ICD-9: 427), and ischemic heart disease (ICD-10: I20-I25, ICD-117 9: 410-414). We included both inpatient and outpatient diagnoses, as well as cause of death 118 119 records in our outcome definition, except for myocardial infarction, which was based on 120 inpatient and cause of death records solely. To ensure specificity of the outcomes studied, only primary, and not underlying, diagnoses were considered for analyses. 121

122 Breast cancer treatment specifics

We extracted the treatment data from the Stockholm-Gotland Breast Cancer Register. 123 Because ~90% of HER-2 positive cancers were treated with trastuzumab between 2005 and 124 2008 in the Stockholm-Gotland region, HER-2 positivity was used as a proxy when no registry 125 data on trastuzumab was available during this time period. Data on adjuvant endocrine therapy 126 127 was verified against the Prescribed Drug Register and categorized into tamoxifen and / or aromatase inhibitor (AI) use. Since radiotherapy to the left breast has, in particular, been 128 implicated in heart complications, radiotherapy was categorized according to tumor laterality 129 130 (left vs. right). Bilateral tumors were coded as receiving left-sided radiotherapy in this analysis. Chemotherapy was coded as anthracycline-based, anthracycline plus taxane-based, 131 fluorouracil cyclophosphamide, methotrexate and (CMF)-based regimens, 132 or unknown/unspecified. 133

Covariates 134

The Stockholm Breast Cancer Register contains data on date of diagnosis, menopausal 135 status at diagnosis and type of surgery (breast conserving surgery vs. mastectomy). Tumor 136 137 characteristics were also retrieved from this register, including tumor size (T), regional lymph node involvement (N) and presence of metastases (M), all from pathology records and 138 summarized in TNM stage as defined according to the American Joint Committee on Cancer 139 140 ("American Joint Committee on Cancer. Breast Cancer Staging. 7th Edition. ,"). Information on inpatient comorbidities at diagnosis was extracted though the Swedish Patient Register and 141 summarized into the Charlson Comorbidity Index (CCI) score, a widely used method for 142 143 classifying chronic comorbid conditions (Charlson, Pompei, Ales, & MacKenzie, 1987). To account for the potential confounding effect from tobacco abuse, chronic pulmonary disease, 144 and hypertension in the associations, we further identified associated diagnoses before cancer 145 146 using ICD codes from the patient register. (Supplementary Table 1)

Statistical analyses 147

We compared the risk of heart diseases in breast cancer patients with that observed in the 148 matched cohort, using flexible parametric model (FPM), overall and stratified by history of 149 respective heart disease and time since diagnosis. We further plotted time-dependent hazard 150 151 ratios using FPM. The FPM is similar to the Cox proportional hazards model in that it provides a HR as measure of association. The key advantage of FPM is that non-proportional hazards 152 can easily be fitted by adding a spline for the interaction with time. Kaplan-Meier curves were 153 154 used to assess the cumulative incidences of heart diseases in breast cancer patients and matched reference individuals. 155

156 Next, we studied the association of adjuvant breast cancer therapy with heart disease risk in breast cancer patients using Cox proportional hazards models. We adjusted these analyses 157 for age and year of diagnosis (model 1), and additionally for menopausal status at diagnosis, 158

cancer stage, type of surgery, CCI score, history of heart disease, hypertension, chronic 159 160 pulmonary disease and tobacco abuse. All treatment specific models were mutually adjusted for adjuvant therapies. Taking the possible selection bias in administration of radiotherapy into 161 162 consideration, the analysis for radiotherapy only included patients receiving radiotherapy, making a comparison between left-sided and right-sided breast cancer (Wadsten et al., 2018). 163 164 Missing indicators were included for the analysis of these covariates in the model. To 165 investigate the robustness of treatment specific associations, a sensitivity analysis was performed excluding breast cancer patients with a history of heart disease. To explore the 166 potential time dependent effect of treatment, we separated the analysis according to different 167 168 follow-up periods, within 10 years after breast cancer diagnosis and beyond, respectively.

All statistical analyses were performed using STATA version 15.1.

170 **RESULTS**

Descriptive characteristics of the study population are described in Table 1. The median age at breast cancer diagnosis was 59 years, with 75% of patients aged less than 65 years (Table 1). Approximately 40% of all patients received adjuvant chemotherapy, with anthracylinebased regimens being most frequently administered. Endocrine therapy was received by more than 80% of patients (constituting mainly of tamoxifen). Of all patients diagnosed between mid-2005 and 2008, 13% were coded as receivers of trastuzumab.

Over a median follow-up of 10.8 years (interquartile range = 6.5 years) arrhythmias were the most frequently reported heart disease (n = 677), followed by ischemic heart disease (n = 384) and heart failure (n = 306). The cumulative incidence of arrhythmias, ischemic heart disease and heart failure in the cohort was 12.10%, 6.55% and 5.59% after 15 years of followup, respectively (Supplementary Figure 2 and Supplementary Table 2).

182

Table 1. Descriptive characteristics of the study population. 184 185

Characteristics	ovoroll
Characteristics	overall (N = 8338)
$\mathbf{X}_{\mathbf{r}}$	(1 = 0.00)
Year of diagnosis. % (N)	25.9 (21.49)
2001-2002	25.8 (2148)
2003-2004	24.3 (2027)
2005-2006	25.8 (2147)
2007-2008	24.2 (2016)
Age at diagnosis. % (N)	
< 50 years	22.3 (1857)
50-65 years	50.8 (4239)
>65 years	26.9 (2242)
Menopausal status. % (N)	
Premenopausal	29.4 (2311)
Postmenopausal	70.6 (5539)
Missing (N)	488
Stage. % (N)	100
Stage I	48.1 (3826)
Stage II	
	39.4 (3131)
Stage III	12.5 (996)
Missing (N)	385
Comorbidity. % (N)	
None	88.6 (7385)
1	6.2 (514)
≥2	5.3 (439)
History of Arrhythmia. % (N)	
No	97.9 (8161)
Yes	2.1 (177)
History of Heart Failure. % (N)	
No	99.5 (8295)
Yes	0.5 (43)
History of Ischemic Heart Disease. % (N)	
No	98.1 (8176)
Yes	1.9 (162)
Surgery. % (N)	1.9 (102)
No	1 1 (00)
	1.1 (90)
Yes, breast-conserving	60.3 (5014)
Yes, mastectomy	38.6 (3205)
Missing (N)	29
Radiotherapy. % (N)	
No, right-sided	11.4 (928)
No, left-sided	11.8 (954)
Yes, right-sided	37.7 (3057)
Yes, left-sided	39.1 (3173)
Missing (N)	226
Chemotherapy. % (N)	
No	59.1 (4830)
Yes	40.9 (3343)
Missing (N)	165
Hormone therapy. % (N)	100
No	18.0(1472)
	18.0 (1472)
Yes, tamoxifen	53.6 (4380)
Yes, aromatase inhibitors	20.3 (1657)
Yes, type unknown	8.1 (664)
Missing (N)	165
Trastuzumab therapy, % (N) *	
No	87.6 (2277)
Yes	12.4 (323)
Missing (N)	1565

186 Missingness on individual variables is less than 5%, except for menopausal status (5.9%, N = 488). Treatment-specific analysis of trastuzumab

187 was restricted to patients diagnosed between 2005 and 2008 (missingness = 37.6%, N = 1565).

188	Overall, breast cancer patients experienced a 27% increased risk (HR = 1.27; 95% CI =
189	1.18-1.37) of developing arrhythmia, and a 38% increased risk of heart failure (HR=1.38; 95%
190	CI = 1.23-1.55) compared to matched reference individuals from general population, while the
191	risk of ischemic heart disease was not increased (HR = 0.93 ; 95% CI = $0.84-1.03$) (Table 2).
192	Hazard ratios of for arrhythmias, ischemic heart disease and heart failure were not notably
193	different in women with or without a previous diagnosis of these respective heart diseases.
194	Analyses by time since diagnosis revealed a short-term increase in risks of arrhythmia and
195	heart failure (Table 2). An elevated risk of ischemic heart disease was observed in the first year
196	after diagnosis (HR = 1.48 ; 95% CI = 1.14 - 1.91), followed by a decline with increasing follow-
197	up time. Interestingly, increased risks for arrhythmia and heart failure were noted beyond 10
198	years (Table 2, Figure 1).

199

201

200 Table 2. Hazard for heart diseases in breast cancer patients compared to the matched cohort.


		Arrhythmia		Heart Failure		Ischemic Heart Disease
	No.	HR (95% CI)	No.	HR (95% CI)	No.	HR (95% CI)
Overall	677	1.27 (1.18-1.37)	306	1.38 (1.23-1.55)	384	0.93 (0.84-1.03)
Corresponding disease history						
No	585	1.28 (1.18-1.39)	286	1.39 (1.23-1.57)	321	0.91 (0.81-1.01)
Yes	92	1.30 (1.04-1.61)	20	1.25 (0.77-2.05)	63	1.04 (0.80-1.36)
Time since diagnosis						
<1 year	109	2.21 (1.81-2.70)	37	2.71 (1.88-3.91)	65	1.48 (1.14-1.91)
1-2 years	48	1.10 (0.82-1.48)	24	1.94 (1.26-3.01)	41	0.97 (0.70-1.34)
2-5 years	123	1.03 (0.86-1.24)	52	1.31 (0.99-1.74)	94	0.92 (0.75-1.13)
5-10 years	226	1.13 (0.99-1.30)	95	1.13 (0.91-1.38)	121	0.84 (0.70-1.00)
10-17 years	171	1.42 (1.22-1.66)	98	1.38 (1.12-1.69)	63	0.79 (0.61-1.01)

202

* Abbreviations: No.=number of cases. HR=hazard ratio. CI = confidence interval. The HRs are estimated using
 flexible parametric model and conditioned on matching criteria (year of birth and history of respective heart
 disease). In all models, time since index date was the underlying time scale and a restricted cubic spline with four
 internal and two boundary knots (five degrees of freedom) placed at quintiles of the event times, was used for the

207 baseline hazard.





211 Figure 1. Time dependent hazard ratio of heart diseases in breast cancer patients comparing to 212 age-matched women.

213 In all models, time since index date was the underlying time scale and a restricted cubic spline with four internal 214 and two boundary knots (five degrees of freedom) placed at quintiles of the event times, was used for the baseline 215 hazard. Time-dependent effects were modelled by adding interaction terms with time using a second spline with 216 three degrees of freedom.

217

Patients treated with chemotherapy and trastuzumab had an increased risk of heart failure 218 compared to patients not receiving these treatments (for patients receiving anthracyclines-based 219 220 chemotherapy, HR=1.99, 95% CI=1.38-2.85; for patients receiving trastuzumab, HR=2.04, 95%CI=1.10-3.80) (Table 3). The risk of heart failure in patients receiving anthracyclines ever 221 222 persisted for 10 years beyond the diagnosis of breast cancer (HR= 2.31, 95%CI=1.21-4.43, 223 supplementary table 3). Receipt of aromatase inhibitors was marginally associated with risk of ischemic heart disease (HR=1.42, 95%CI=1.00-2.01 compared to patients without hormonal 224 therapy), but not with risk of heart failure or arrhythmias (Table 3). A direct comparison 225 226 between left-sided and right-sided radiotherapy, showed no evidence of an association of radiotherapy with heart disease except for a somewhat increased risk of ischemic heart disease 227 228 in women with left sided breast cancer, particularly after 10 years after cancer diagnosis, although not statistically significant (HR= 1.14, 95%CI=0.89-1.46; HR for the risk beyond 10 229 years=1.32, 95%CI=0.74-2.36). Sensitivity analyses excluding breast cancer patients with a 230 231 previous history of heart disease only slightly changed the point estimates of the treatment effects but not the inferences (Supplementary Table 4). 232

	Total	HR	(95% CI) for Ari	hythmia	HR	(95% CI) for hear	t failure	HR	(95% CI) for iscl	hemic heart diseas
Treatment variables	No.	Ν	Model1	Model2	Ν	Model1	Model2	Ν	Model 1	Model2
Radiotherapy										
Right-sided	3057	251	REF (1.00)	REF (1.00)	102	REF (1.00)	REF (1.00)	121	REF (1.00)	REF (1.00)
Left-sided	3173	244	0.93 (0.78-1.11)	0.91 (0.76-1.08)	104	0.96 (0.73-1.26)	0.99 (0.76-1.31)	141	1.11 (0.87-1.42)	1.14 (0.89-1.46)
Missing	226	13	-	-	14	-	-	9	-	-
Chemotherapy										
No	4830	454	REF (1.00)	REF (1.00)	176	REF (1.00)	REF (1.00)	262	REF (1.00)	REF (1.00)
Anthracyclines-based	1458	96	1.12 (0.90-1.41)	0.99 (0.77-1.28)	58	2.26 (1.66-3.08)	1.99 (1.38-2.85)	50	1.11 (0.81-1.52)	1.10 (0.78-1.57)
Anthracyclines+Taxanes	295	10	0.88 (0.47-1.67)	0.75 (0.39-1.45)	13	5.55 (3.05-10.08)	4.39 (2.31-8.37)	7	1.31 (0.60-2.82)	1.20 (0.54-2.67)
CMF	108	13	1.62 (0.93-2.82)	1.39 (0.79-2.47)	5	1.57 (0.64-3.84)	1.12 (0.45-2.79)	5	1.01 (0.41-2.45)	0.69 (0.28-1.70)
Type unknown	1482	93	1.21 (0.96-1.53)	1.15 (0.87-1.51)	43	1.87 (1.32-2.66)	1.65 (1.09-2.49)	55	1.38 (1.02-1.87)	1.44 (1.01-2.07)
Missing	165	11	-	-	11	-	-	5	-	-
Hormone therapy										
No	1472	101	REF (1.00)	REF (1.00)	55	REF (1.00)	REF (1.00)	57	REF (1.00)	REF (1.00)
Tamoxifen	4380	345	0.94 (0.75-1.17)	1.03 (0.81-1.31)	125	0.61 (0.45-0.84)	0.84 (0.60-1.18)	168	0.79 (0.58-1.07)	0.90 (0.65-1.24)
Aromatase inhibitors	1657	159	1.16 (0.90-1.51)	1.09 (0.83-1.43)	82	1.13 (0.79-1.62)	1.08 (0.74-1.57)	109	1.41 (1.00-1.97)	1.42 (1.00-2.01)
Type unknown	664	61	0.85 (0.61-1.19)	0.91 (0.65-1.28)	33	0.72 (0.46-1.13)	0.95 (0.59-1.51)	45	1.05 (0.70-1.58)	1.25 (0.82-1.89)
Missing	165	11	-	-	11	-	-	5	-	-
Trastuzumab *										
No	2277	160	REF (1.00)	REF (1.00)	52	REF (1.00)	REF (1.00)	81	REF (1.00)	REF (1.00)
Yes	323	21	1.17 (0.74-1.84)	1.42 (0.87-2.31)	15	2.69 (1.51-4.80)	2.04 (1.10-3.80)	15	1.63 (0.94-2.83)	1.48 (0.82-2.67)
Missing	1565	115	-	-	53	-	-	63	-	-

233 **Table 3.** Hazard ratios for heart diseases by different adjuvant therapies

Abbreviations: Total No. refers to the total number of patients. N events refers to the number of observed cases. HR = hazard ratio; CI = confidence interval. Hazard ratios are estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios for model 1 are adjusted for age and calendar period. Hazard ratios for model 2 are multivariable adjusted including age at diagnosis (years), year of diagnosis (2001/2002, 2003/2004, 2005/2006, 2007/2008), menopausal status (premenopausal, postmenopausal, unknown), Charlson comorbidity index (0, 1, \geq 2), clinical stage (I, II, III, unknown), type of surgery (no, partial mastectomy, total mastectomy, unknown), history of the specific heart disease, hypertension, chronic pulmonary disease and tobacco abuse, and all treatment variables listed in the table. * Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

240

241

242

243

245 DISCUSSION

In a population-based setting, we demonstrated that the incidence of heart disease in breast cancer patients was significantly higher than the incidence observed in matched reference individuals from the general population. The risks of arrhythmia and heart failure were increased even beyond 15 years after diagnosis. Receipt of trastuzumab, as well as administration of anthracycline +/- taxane-based regimens were independently associated with an increased risk of heart failure, while aromatase inhibitor therapy was associated with an increased risk of ischemic heart disease.

We found an increased risk of arrhythmia and heart failure in breast cancer patients as compared with the matched reference individuals from the general population, which is similar to the risk of heart failure reported by a previous Dutch study (Hooning et al., 2007), indicating the generalizability of our findings within European countries. In the present study, we further found similar magnitude HRs estimates in patients with and without a previous diagnosis of heart disease, suggesting no effect modification by disease history.

Analysis by time since diagnosis from the current study revealed long-term increased risks 259 of arrhythmia and heart failure following breast cancer. The long-term increased risk of heart 260 failure potentially reflects the profound cardiotoxic effect of anthracyclines, as we found 261 262 increased risk of heart failure in patients treated with anthracyclines beyond 10 years after cancer diagnosis. As the long-term risk was observed for heart failure but not ischemic heart 263 disease, we hypothesized that the cardiotoxic effect of chemotherapy was mainly on the 264 265 myocardium but not the cardiac vessels. The finding that risk of ischemic heart disease in breast cancer patients may be shortly elevated after diagnosis, but diminish over time is not 266 unexpected, considering the emotional distress of dealing with a new cancer diagnosis in the 267 patients, which may lead to higher short-term rates of ischemic heart disease (Fang et al., 2012; 268 Schoormans, Pedersen, Dalton, Rottmann, & van de Poll-Franse, 2016). 269

The findings that administration of anthracycline +/- taxanes, as well as trastuzumab are 270 271 associated with increased risks of heart failure are in agreement with previous observational studies (Bowles et al., 2012; Chavez-MacGregor et al., 2013; Doyle et al., 2005; Du et al., 2009; 272 273 Goldhar et al., 2016; Thavendiranathan et al., 2016) and clinical trials (Chen et al., 2011) in specific subgroups of breast cancer patients. While (poly)chemotherapy is thought to lead to 274 275 heart failure through a plethora of mechanisms that damage cardiomyocytes (Yeh & Bickford, 276 2009), taxanes may also interrupt the metabolism and excretion of anthracyclines, hence accentuating their toxicity (Bird & Swain, 2008). Inhibition of the HER2 receptors in myocytes, 277 which regulates cell development and growth may largely explain the cardiotoxicity caused by 278 279 trastuzumab (Yeh & Bickford, 2009).

Population-based estimates of incidence of ischemic heart disease following treatment with 280 aromatase inhibitors have not been extensively reported in the literature (Matthews et al., 2018). 281 282 Abdel-Qadir, et al also found an increased risk of myocardial infarction in patients treated with aromatase inhibitors, as compared to those treated with tamoxifen (Abdel-Qadir et al., 2016). 283 It has been posited that this apparent increase in risk of ischemic heart disease might in fact be 284 attributed to reduced risk of heart disease following tamoxifen treatment (Hackshaw et al., 285 286 2011; Rosell et al., 2013). Nonetheless, given that in the present study, an increased risk of 287 ischemic heart disease was observed in patients treated with aromatase inhibitors compared to patients not receiving hormone treatment, prior hypothesis that this observation is explained by 288 the protective effect of tamoxifen is not fully correct. 289

While several previous studies have shown that radiotherapy for breast cancer increase the risk of ischemic heart disease and heart failure (Darby et al., 2013; Harris et al., 2006; Pinder et al., 2007), some studies, particularly those including patients diagnosed in recent decades, have not seen such increase (Boekel et al., 2014; Wadsten et al., 2018; Wennstig et al., 2020). Indeed, the time trends of heart dose improvement and the use of modern heart dose sparing

techniques, together with individualized doses of therapy, may result in lower doses of radiation 295 296 to the heart (C. Taylor et al., 2017; C. W. Taylor & Kirby, 2015; C. W. Taylor et al., 2009). Another reason for inconsistent results in the literature could be that patients with a left sided 297 breast cancer who are susceptible to cardiovascular disease are less likely to be selected for 298 radiotherapy (C. W. Taylor & Kirby, 2015). Therefore, in our study, we compared risk of 299 300 ischemic heart disease in patients treated with radiotherapy for left-sided to those treated for 301 right-sided breast cancer. We found slightly increased non-significant risk of ischemic heart disease, this risk appeared (as expected) more pronounced in the follow-up period after 10 302 years. Overall, our results indicate only small risk of heart disease due to radiotherapy in women 303 304 treated in Sweden after year 2000.

A major strength of our study is that we were able to investigate risks of heart disease by time since diagnosis and adjuvant treatment. The risk estimates presented in this study therefore provide an insight into the short-term and long-term unintended effects of adjuvant breast cancer therapy in routine clinical practice. Notably, all breast cancer patients were followed-up for a relatively long period. The population-based nature of the study and linkage to registrybased data further minimized the risk of selection and information biases.

311 We acknowledge several limitations. The Swedish Patient Register has high validity for 312 heart failure, arrhythmia and ischemic heart disease (with positive predictive value between 88%-98%) (Hammar et al., 2001; Ludvigsson et al., 2011), but some misclassification of heart 313 diseases may have occurred. We further tried to reduce the likelihood of misclassification by 314 315 analysing main diagnoses only. Secondly, we did not have complete data on trastuzumab during the study period and relied on HER-2 status as proxy, which may have resulted in some 316 317 misclassification. The numbers of heart disease after trastuzumab and taxane were also relatively small in our study, and might have resulted in limited power or chance finding when 318 319 identifying an association between trastuzumab/taxane and the relevant cardiac events. Besides,

the Stockholm-Gotland Breast Cancer Register only records intended treatment with radiotherapy and chemotherapy, not whether patients were actually administrated with these therapies. Finally, it should be noted that cancer patients are subject to increased medical surveillance, especially in the initial period after diagnosis. This could explain the increased rates of heart disease events especially within the first year of follow-up, although psychological distress following recent diagnosis with cancer represents an alternative plausible explanation for this observation (Fang et al., 2012; Schoormans et al., 2016).

327

Through this study, we demonstrate that compared to the general population, women with breast cancer are associated with significantly increased risks of cardiovascular events including heart failure and arrhythmia. The short term risk of ischemic heart disease diminished after 1 year post diagnosis. The increased risk of arrhythmia and heart failure however appears to persist long-term, beyond the first decade after diagnosis. The risk estimates observed in this study may serve as reference to aid adjuvant therapy decision-making and patient counselling in oncology practices.

335

336 **DECLARATIONS:**

337 **Competing interests:** The authors declare no competing interest.

338 Ethics approval and consent to participate

The study was approved by the Regional Ethical Review Board in Stockholm (Dnr 2009/25431/4).

341 Author contributions:

342 HY had full access to all of the data in the study and takes responsibility for the integrity343 of the data and the accuracy of the data analysis. KC, NBP and HY conceived and designed the

344 study. All authors acquired, analyzed, or interpreted the data. HY and NBP drafted the 345 manuscript. All authors critically revised the manuscript for important intellectual content. HY 346 performed the statistical analysis. KC, NBP and HY obtained the funding. All authors read and 347 approved the final manuscript.

348

349 Funding

350 This work was supported by the Swedish Research Council [grant no: 2018-02547]; Swedish Cancer Society [grant no: CAN-19-0266] and FORTE [grant no: 2016-00081]. HY was 351 supported by Startup Fund for high-level talents of Fujian Medical University [grant no: 352 XRCZX2020007] and Startup Fund for scientific research, Fujian Medical University [grant 353 no: 2019QH1002]. NBP was supported by the University of Malaya Impact-Oriented 354 Interdisciplinary Research Grant Programme [grant no: IIRG006C-19HWB]. WB was partly 355 supported by China Scholarship council. Dr Ludvigsson coordinates a study on behalf of the 356 357 Swedish IBD quality register (SWIBREG), which has received funding from Janssen corporation. The funders had no role in the study design, data collection, analyses, data 358 interpretation, writing the manuscript, or in the decision to submit the manuscript for 359 publication. 360

361 Acknowledgements

362 Not applicable.

363 Availability of data and materials

The register-based cohort datasets linked and analyzed in the current study are not publicly available due to Swedish law, but are available by applying through the Swedish National Board of Health and Welfare and Statistics Sweden. Detailed information on data application can be found using the following links https://bestalladata.socialstyrelsen.se/datafor-forskning/ and https://www.scb.se/vara-tjanster/bestalla-mikrodata/.

369 Consent to publish

- All authors approved the manuscript and consented to its publication. 370
- Authors' information 371
- Not applicable. 372
- 373
- REFERENCES 374

375	Abdel-Qadir, H., Amir, E., Fischer, H. D., Fu, L., Austin, P. C., Harvey, P. J., Anderson, G. M. (2016).
376	The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-
377	menopausal women with early stage breast cancer. European journal of cancer, 68, 11-21.
378	doi:10.1016/j.ejca.2016.08.022
379	American Joint Committee on Cancer. Breast Cancer Staging. 7th Edition Retrieved from Available
380	at https://cancerstaging.org/references-tools/quickreferences/Documents/BreastLarge.pdf
381	Bird, B. R., & Swain, S. M. (2008). Cardiac toxicity in breast cancer survivors: review of potential
382	cardiac problems. Clin Cancer Res, 14(1), 14-24. Retrieved from
383	https://www.ncbi.nlm.nih.gov/pubmed/18172247. doi:10.1158/1078-0432.CCR-07-1033
384	Boekel, N. B., Schaapveld, M., Gietema, J. A., Rutgers, E. J., Versteegh, M. I., Visser, O., van
385	Leeuwen, F. E. (2014). Cardiovascular morbidity and mortality after treatment for ductal
386	carcinoma in situ of the breast. Journal of the National Cancer Institute, 106(8). Retrieved
387	from https://www.ncbi.nlm.nih.gov/pubmed/25128694 . doi:10.1093/jnci/dju156
388	Bowles, E. J., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T.,
389	Pharmacovigilance Study, T. (2012). Risk of heart failure in breast cancer patients after
390	anthracycline and trastuzumab treatment: a retrospective cohort study. Journal of the
391	National Cancer Institute, 104(17), 1293-1305. Retrieved from
392	https://www.ncbi.nlm.nih.gov/pubmed/22949432.doi:10.1093/jnci/djs317
393	Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E.,
394	Herceptin Adjuvant Trial Study, T. (2017). 11 years' follow-up of trastuzumab after adjuvant
395	chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant
396	(HERA) trial. <i>Lancet, 389</i> (10075), 1195-1205. Retrieved from
397	https://www.ncbi.nlm.nih.gov/pubmed/28215665.doi:10.1016/S0140-6736(16)32616-2
398	Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying
399	prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis,
400	40(5), 373-383. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/3558716 .
401	doi:10.1016/0021-9681(87)90171-8
402	Chavez-MacGregor, M., Zhang, N., Buchholz, T. A., Zhang, Y., Niu, J., Elting, L., Giordano, S. H.
403	(2013). Trastuzumab-related cardiotoxicity among older patients with breast cancer. Journal
404	of clinical oncology : official journal of the American Society of Clinical Oncology, 31(33),
405	4222-4228. Retrieved from https://pubmed.ncbi.nlm.nih.gov/24127446
406	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821011/. doi:10.1200/JCO.2013.48.7884
407	Chen, T., Xu, T., Li, Y., Liang, C., Chen, J., Lu, Y., Wu, S. (2011). Risk of cardiac dysfunction with
408	trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev, 37(4), 312-320.
409	Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/20952131</u> .
410	doi:10.1016/j.ctrv.2010.09.001
411	Chung, I. Y., Lee, J. W., Moon, HG., Shin, K. H., Han, W., Son, B. H., Noh, DY. (2020). Effect of
412	standard low-dose anthracycline chemotherapy on late congestive heart failure in breast
413	cancer survivors aged between 50 and 59 at diagnosis: A nationwide study. The Breast, 53,
414	125-129. Retrieved from

415	http://www.sciencedirect.com/science/article/pii/S096097762030148X.
416	doi: <u>https://doi.org/10.1016/j.breast.2020.07.006</u>
417	Colzani, E., Liljegren, A., Johansson, A. L., Adolfsson, J., Hellborg, H., Hall, P. F., & Czene, K. (2011a).
418	Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis,
419	age, and tumor characteristics. Journal of clinical oncology : official journal of the American
420	Society of Clinical Oncology, 29(30), 4014-4021. Retrieved from
421	http://www.ncbi.nlm.nih.gov/pubmed/21911717. doi:10.1200/JCO.2010.32.6462
422	Colzani, E., Liljegren, A., Johansson, A. L., Adolfsson, J., Hellborg, H., Hall, P. F., & Czene, K. (2011b).
423	Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis,
424	age, and tumor characteristics. Journal of clinical oncology : official journal of the American
425	Society of Clinical Oncology, 29(30), 4014-4021. Retrieved from
426	http://www.ncbi.nlm.nih.gov/pubmed/21911717
427	http://jco.ascopubs.org/content/29/30/4014.full.pdf. doi:10.1200/JCO.2010.32.6462
428	Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., Hall, P.
429	(2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J
430	<i>Med, 368</i> (11), 987-998. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/23484825</u> .
431	doi:10.1056/NEJMoa1209825
432	Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., & Hershman, D. L. (2005). Chemotherapy and
433	cardiotoxicity in older breast cancer patients: a population-based study. <i>Journal of clinical</i>
434	oncology : official journal of the American Society of Clinical Oncology, 23(34), 8597-8605.
435	Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/16314622</u> .
436	doi:10.1200/JCO.2005.02.5841
437	Du, X. L., Xia, R., Liu, C. C., Cormier, J. N., Xing, Y., Hardy, D., Burau, K. (2009). Cardiac toxicity
438	associated with anthracycline-containing chemotherapy in older women with breast cancer.
439	<i>Cancer, 115</i> (22), 5296-5308. Retrieved from
440	https://www.ncbi.nlm.nih.gov/pubmed/19672997. doi:10.1002/cncr.24621
441	Early Breast Cancer Trialists' Collaborative, G. (2005). Effects of chemotherapy and hormonal therapy
442	for early breast cancer on recurrence and 15-year survival: an overview of the randomised
443	trials. <i>Lancet, 365</i> (9472), 1687-1717. Retrieved from
444	http://www.ncbi.nlm.nih.gov/pubmed/15894097. doi:10.1016/S0140-6736(05)66544-0
445	Early Breast Cancer Trialists' Collaborative, G. (2012). Comparisons between different
446	polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome
447	among 100 000 women in 123 randomised trials. The Lancet, 379(9814), 432-444. Retrieved
448	from http://www.sciencedirect.com/science/article/pii/S0140673611616255.
449	doi: <u>https://doi.org/10.1016/S0140-6736(11)61625-5</u>
450	Early Breast Cancer Trialists' Collaborative, G., Dowsett, M., Forbes, J. F., Bradley, R., Ingle, J., Aihara,
451	T., Gray, R. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-
452	level meta-analysis of the randomised trials. Lancet, 386(10001), 1341-1352. Retrieved from
453	http://www.ncbi.nlm.nih.gov/pubmed/26211827
454	http://spiral.imperial.ac.uk/bitstream/10044/1/32438/8/1-s2.0-S0140673615610741-main.pdf.
455	doi:10.1016/S0140-6736(15)61074-1
456	Fang, F., Fall, K., Mittleman, M. A., Sparen, P., Ye, W., Adami, H. O., & Valdimarsdottir, U. (2012).
457	Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med, 366(14), 1310-1318.
458	Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22475594
459	http://www.nejm.org/doi/pdf/10.1056/NEJMoa1110307. doi:10.1056/NEJMoa1110307
460	Foukakis, T., von Minckwitz, G., Bengtsson, N. O., Brandberg, Y., Wallberg, B., Fornander, T.,
461	Colorectal Cancer Study, G. (2016). Effect of Tailored Dose-Dense Chemotherapy vs Standard
462	3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-
463	Risk Early Breast Cancer: A Randomized Clinical Trial. JAMA, 316(18), 1888-1896. Retrieved
464	from https://www.ncbi.nlm.nih.gov/pubmed/27825007. doi:10.1001/jama.2016.15865
465	Goldhar, H. A., Yan, A. T., Ko, D. T., Earle, C. C., Tomlinson, G. A., Trudeau, M. E., Chan, K. K.
466	(2016). The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast

467	Cancer Patients: A Population Study. <i>Journal of the National Cancer Institute</i> , 108(1).
468	Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/26476433</u> . doi:10.1093/jnci/djv301
469	Goldvaser, H., Korzets, Y., Shepshelovich, D., Yerushalmi, R., Sarfaty, M., Ribnikar, D., Amir, E.
470	(2019). Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A
471	Systemic Review and Meta-Analysis. JNCI cancer spectrum, 3(2), pkz033-pkz033. Retrieved
472	from <u>https://pubmed.ncbi.nlm.nih.gov/31360906</u>
473	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649709/. doi:10.1093/jncics/pkz033
474	Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., Zambetti, M. (2019). Increasing the
475	dose intensity of chemotherapy by more frequent administration or sequential scheduling: a
476	patient-level meta-analysis of 37 298 women with early breast cancer in 26
477	randomised trials. The Lancet, 393(10179), 1440-1452. Retrieved from
478	https://doi.org/10.1016/S0140-6736(18)33137-4. doi:10.1016/S0140-6736(18)33137-4
479	Hackshaw, A., Roughton, M., Forsyth, S., Monson, K., Reczko, K., Sainsbury, R., & Baum, M. (2011).
480	Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial
481	in Women at Least 50 Years of Age With Early Breast Cancer. Journal of Clinical Oncology,
482	29(13), 1657-1663. Retrieved from https://ascopubs.org/doi/abs/10.1200/JCO.2010.32.2933.
483	doi:10.1200/jco.2010.32.2933
484	Hammar, N., Alfredsson, L., Rosen, M., Spetz, C. L., Kahan, T., & Ysberg, A. S. (2001). A national record
485	linkage to study acute myocardial infarction incidence and case fatality in Sweden. Int J
486	Epidemiol, 30 Suppl 1, S30-34. Retrieved from
487	https://www.ncbi.nlm.nih.gov/pubmed/11759848. doi:10.1093/ije/30.suppl_1.s30
488	Harris, E. E., Correa, C., Hwang, W. T., Liao, J., Litt, H. I., Ferrari, V. A., & Solin, L. J. (2006). Late cardiac
489	mortality and morbidity in early-stage breast cancer patients after breast-conservation
490	treatment. Journal of clinical oncology : official journal of the American Society of Clinical
491	<i>Oncology, 24</i> (25), 4100-4106. Retrieved from
492	https://www.ncbi.nlm.nih.gov/pubmed/16908933. doi:10.1200/JCO.2005.05.1037
493	Holm, J., Li, J., Darabi, H., Eklund, M., Eriksson, M., Humphreys, K., Czene, K. (2016). Associations
494	of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis. Journal of
495	Clinical Oncology, 34(3), 251-258. Retrieved from
496	https://ascopubs.org/doi/abs/10.1200/JCO.2015.63.0624. doi:10.1200/jco.2015.63.0624
497	Hooning, M. J., Botma, A., Aleman, B. M., Baaijens, M. H., Bartelink, H., Klijn, J. G., van Leeuwen,
498	F. E. (2007). Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
499	Journal of the National Cancer Institute, 99(5), 365-375. Retrieved from
500	http://www.ncbi.nlm.nih.gov/pubmed/17341728
501	http://jnci.oxfordjournals.org/content/99/5/365.full.pdf. doi:10.1093/jnci/djk064
502	Khosrow-Khavar, F., Filion, K. B., Bouganim, N., Suissa, S., & Azoulay, L. (2020). Aromatase Inhibitors
503	and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based
504	Cohort Study. <i>Circulation, 141</i> (7), 549-559. Retrieved from
505	https://www.ncbi.nlm.nih.gov/pubmed/32065766.
506	doi:10.1161/CIRCULATIONAHA.119.044750
507	Khouri, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L.
508	W. (2012). Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the
509	unresolved issues. <i>Circulation, 126</i> (23), 2749-2763. Retrieved from
510	https://www.ncbi.nlm.nih.gov/pubmed/23212997.
511	doi:10.1161/CIRCULATIONAHA.112.100560
512	Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J. L., Reuterwall, C., Olausson, P. O.
513	(2011). External review and validation of the Swedish national inpatient register. <i>BMC Public</i>
514	Health, 11, 450. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21658213
515	http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142234/pdf/1471-2458-11-450.pdf.
516	doi:10.1186/1471-2458-11-450
510	401.10.1100/17/1 2700 11 700

517	Matthews, A., Stanway, S., Farmer, R. E., Strongman, H., Thomas, S., Lyon, A. R., Bhaskaran, K.
518	(2018). Long term adjuvant endocrine therapy and risk of cardiovascular disease in female
519	breast cancer survivors: systematic review. BMJ, 363. doi:10.1136/BMJ.K3845
520	Papakonstantinou, A., Matikas, A., Bengtsson, N. O., Malmstrom, P., Hedayati, E., Steger, G.,
521	Bergh, J. (2020). Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and
522	trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER
523	trial. <i>Cancer, 126</i> (6), 1175-1182. Retrieved from
524	https://www.ncbi.nlm.nih.gov/pubmed/31851385. doi:10.1002/cncr.32653
525	Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007). Congestive heart
526	failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
527	Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
528	25(25), 3808-3815. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17664460
529	http://jco.ascopubs.org/content/25/25/3808.full.pdf. doi:10.1200/JCO.2006.10.4976
530	Rosell, J., Nordenskjöld, B., Bengtsson, NO., Fornander, T., Hatschek, T., Lindman, H.,
531	Carstensen, J. (2013). Effects of adjuvant tamoxifen therapy on cardiac disease: results from
532	a randomized trial with long-term follow-up. <i>Breast cancer research and treatment, 138</i> (2),
533	467-473. Retrieved from <u>https://doi.org/10.1007/s10549-013-2457-6</u> . doi:10.1007/s10549-
534	013-2457-6
535	Schoormans, D., Pedersen, S. S., Dalton, S., Rottmann, N., & van de Poll-Franse, L. (2016).
536	Cardiovascular co-morbidity in cancer patients: the role of psychological distress. <i>Cardio-</i>
537	Oncology, 2(1), 9. Retrieved from <u>https://doi.org/10.1186/s40959-016-0019-x</u> .
538	doi:10.1186/s40959-016-0019-x
539	
539 540	Taylor, C., Correa, C., Duane, F. K., Aznar, M. C., Anderson, S. J., Bergh, J., Early Breast Cancer Trialists' Collaborative, G. (2017). Estimating the Risks of Breast Cancer Radiotherapy:
541	Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous
542	Randomized Trials. Journal of clinical oncology : official journal of the American Society of
543	<i>Clinical Oncology, 35</i> (15), 1641-1649. Retrieved from
544	https://www.ncbi.nlm.nih.gov/pubmed/28319436. doi:10.1200/JCO.2016.72.0722
545	Taylor, C. W., & Kirby, A. M. (2015). Cardiac Side-effects From Breast Cancer Radiotherapy. <i>Clin Oncol</i>
546	(<i>R Coll Radiol</i>), 27(11), 621-629. Retrieved from
547	https://www.ncbi.nlm.nih.gov/pubmed/26133462. doi:10.1016/j.clon.2015.06.007
548	Taylor, C. W., Nisbet, A., McGale, P., Goldman, U., Darby, S. C., Hall, P., & Gagliardi, G. (2009). Cardiac
549	doses from Swedish breast cancer radiotherapy since the 1950s. <i>Radiother Oncol, 90</i> (1), 127-
550	135. doi:10.1016/j.radonc.2008.09.029
551	Thavendiranathan, P., Abdel-Qadir, H., Fischer, H. D., Camacho, X., Amir, E., Austin, P. C., & Lee, D. S.
552	(2016). Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in
553	Routine Clinical Practice: A Population-Based Cohort Study. Journal of clinical oncology :
554	official journal of the American Society of Clinical Oncology, 34(19), 2239-2246. Retrieved
555	from <u>https://www.ncbi.nlm.nih.gov/pubmed/27091709</u> . doi:10.1200/JCO.2015.65.1505
556	Wadsten, C., Wennstig, A. K., Garmo, H., Nilsson, G., Blomqvist, C., Holmberg, L., Sund, M. (2018).
557	Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. Breast cancer
558	research and treatment, 171(1), 95-101. doi:10.1007/s10549-018-4803-1
559	Wennstig, AK., Wadsten, C., Garmo, H., Fredriksson, I., Blomqvist, C., Holmberg, L., Sund, M.
560	(2020). Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer:
561	results from a large population-based cohort. Breast Cancer Research, 22(1), 10. Retrieved
562	from <u>https://doi.org/10.1186/s13058-020-1249-2</u> . doi:10.1186/s13058-020-1249-2
563	Wigertz, A., Ahlgren, J., Holmqvist, M., Fornander, T., Adolfsson, J., Lindman, H., Lambe, M.
564	(2012). Adherence and discontinuation of adjuvant hormonal therapy in breast cancer
565	patients: a population-based study. <i>Breast cancer research and treatment, 133</i> (1), 367-373.
566	Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22286315 . doi:10.1007/s10549-012-
567	1961-4

- 568 Yeh, E. T., & Bickford, C. L. (2009). Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol, 53(24), 2231-2247. Retrieved 569 from https://www.ncbi.nlm.nih.gov/pubmed/19520246. doi:10.1016/j.jacc.2009.02.050 570 571
- 572

573

574 ONLINE SUPPLEMENT	ARY
-----------------------	-----

- 576 Supplementary Table 1. ICD codes used in the analyses
- 577 Supplementary Table 2. Cumulative incidence estimates of heart diseases in breast cancer
- 578 patients and age matched controls.
- 579 Supplementary Table 3. Hazard ratios for heart diseases by different adjuvant therapies and
- 580 time since diagnosis.
- 581 Supplementary Table 4. Hazard ratios for heart diseases by different adjuvant therapies,
- 582 excluding patients with a history of heart diseases.
- 583 **Supplementary Figure 1.** Flow chart of the data.
- Supplementary Figure 2. Cumulative incidence of heart disease in breast cancer patients and matched
 women.
- 586 Kaplan-Meier estimates of the cumulative risk of heart disease by time since diagnosis, in breast cancer
- 587 patients and matched women from the general population. BC: breast cancer; REF: reference women in
- the matched controls from the general population; No.: number.

Supplementary Table 1. ICD codes used in the analyses.

Disease codes	ICD-10	ICD-9
Arrhythmia	I47, I48, I49	427
Atrial fibrillation	I48	427D
Tachycardia and other cardiac arrhythmias	I47, I49	427A-C, 427E-J
Heart failure	I50	428A, 428B, 428X
Ischemic heart disease	120-125	410-414
Myocardial infarction	I21,I22	410
Angina pectoris	I20	411B, 413, 414A
Hypertension	I10-I15	401-405
Tobacco abuse and Chronic Pulmonary	J40-J47,J60-J67,F17,	490-496,500-505,416W,416X,
Disease	I278,I279,J684,J701,J703	506E,508B,508W,305B

592 593

Abbreviations: ICD = International Classification of Diseases.

Supplementary Table 2. Cumulative incidence estimates of heart diseases in breast cancer patients and matched controls.

	Cumulative incidence, % (95% CI)							
	6 month	1 year	2 years	5 years	10 years	15 years		
Arrhythmia								
Breast cancer	0.86 (0.68-1.08)	1.32 (1.10-1.59)	1.92 (1.65-2.25)	3.60 (3.21-4.04)	7.10 (6.52-7.73)	12.10 (11.12-13.16)		
Matched control	0.33 (0.29-0.37)	0.60 (0.55-0.65)	1.15 (1.08-1.23)	2.78 (2.67-2.90)	5.91 (5.75-6.08)	9.60 (9.36-9.86)		
Heart failure								
Breast cancer	0.20 (0.13-0.33)	0.45 (0.33-0.62)	0.75 (0.58-0.96)	1.46 (1.21-1.75)	2.93 (2.56-3.35)	5.59 (4.91-6.37)		
Matched control	0.08 (0.06-0.10)	0.17 (0.14-0.20)	0.32 (0.29-0.36)	0.86 (0.80-0.93)	2.19 (2.09-2.29)	4.37 (4.19-4.56)		
Ischemic heart disease								
Breast cancer	0.46 (0.33-0.63)	0.79 (0.62-1.00)	1.30 (1.08-1.57)	2.57 (2.24-2.95)	4.43 (3.97-4.93)	6.55 (5.85-7.34)		
Matched control	0.23 (0.20-0.27)	0.54 (0.49-0.59)	1.07 (1.00-1.14)	2.45 (2.35-2.56)	4.68 (4.54-4.83)	7.01 (6.80-7.22)		

Abbreviations: CI = confidence interval. Cumulative incidence estimates of heart diseases in all breast cancer patients (N = 8338) at different time-points following the index date (= date of diagnosis in breast cancer patients). Cumulative incidence estimates are obtained from Kaplan-Meier survival analyses.

Supplementary Table 3. Hazard ratios for heart diseases by different adjuvant therapies and time since diagnosis 606

	HR (95% CI) for Arrhythmia		HR (95% CI) for heart failure		HR (95% CI) for ischemic heart disea	
Treatment variables	<10y	>10y	<10y	>10y	<10y	>10y
Radiotherapy						
Right-sided	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Left-sided	0.94 (0.76-1.16)	0.83 (0.59-1.16)	1.02 (0.73-1.43)	0.92 (0.57-1.48)	1.10 (0.84-1.44)	1.32 (0.74-2.36)
Missing						
Chemotherapy						
No	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Anthracyclines-based	1.02 (0.76-1.36)	1.00 (0.58-1.73)	1.84 (1.19-2.85)	2.31 (1.21-4.43)	1.09 (0.75-1.60)	1.18 (0.48-2.90)
Anthracyclines +Taxanes	0.75 (0.37-1.50)	0.75 (0.10-5.62)	5.08 (2.56-10.06)	0.00 (0.00)	1.28 (0.57-2.86)	0.00 (0.00-0.00)
CMF	1.74 (0.93-3.25)	0.72 (0.17-3.00)	1.33 (0.47-3.73)	0.69 (0.09-5.17)	0.67 (0.24-1.85)	0.92 (0.12-7.10)
Type unknown	1.18 (0.86-1.63)	1.09 (0.63-1.89)	1.75 (1.06-2.86)	1.38 (0.66-2.89)	1.47 (0.99-2.19)	1.31 (0.52-3.27)
Missing						
Hormone therapy						
No	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Tamoxifen	1.02 (0.77-1.34)	1.10 (0.69-1.77)	0.76 (0.50-1.14)	1.06 (0.58-1.96)	0.82 (0.58-1.16)	1.36 (0.60-3.09)
Aromatase inhibitors	1.09 (0.81-1.48)	1.05 (0.56-1.96)	0.92 (0.60-1.41)	1.62 (0.76-3.46)	1.36 (0.93-1.97)	1.39 (0.48-4.06)
Type unknown	0.76 (0.49-1.20)	1.19 (0.68-2.09)	0.91 (0.49-1.69)	1.08 (0.51-2.29)	1.20 (0.75-1.92)	1.44 (0.54-3.83)
Missing						
Trastuzumab *						
No	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Yes	1.48 (0.90-2.43)	0.00 (0.00-0.00)	2.26 (1.20-4.27)	0.00 (0.00-0.00)	1.41 (0.76-2.59)	4.43 (0.39-49.76)
Missing						

Abbreviations: Total No. refers to the total number of patients. N events refers to the number of observed cases. HR = hazard ratio; CI = confidence interval. Hazard ratios are estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios for model1 are adjusted for age and calendar period. Hazard ratios for model2 are multivariable adjusted including age at diagnosis (years), year of diagnosis (2001/2002, 2003/2004, 2005/2006, 2007/2008), menopausal status (premenopausal, postmenopausal, unknown), Charlson comorbidity index (0, 1, \geq 2), clinical stage (I, II, III, unknown), type of surgery (no, partial mastectomy, total mastectomy, unknown), history of the specific heart disease, hypertension, chronic pulmonary disease and tobacco abuse, and all treatment variables listed in the table. * Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

612	Supplementary Table 4. Hazard ratios for heart diseases by different adjuvant therapies, excluding patients with a history of heart diseases	
613		

	Arrhythm $(N = 570)$	ia	Heart fail (N =243)	ure	Ischemic I (N =307)	heart disease
Treatment variables	N events	HR (95% CI)	N events	HR (95% CI)	N events	HR (95%)
Radiotherapy						
Right-sided	218	REF (1.00)	83	REF (1.00)	99	REF (1.00)
Left-sided	208	0.91 (0.75-1.10)	87	1.01 (0.74-1.36)	118	1.14 (0.87-1.49)
Missing	10		6		5	
Chemotherapy						
No	376	REF (1.00)	133	REF (1.00)	207	REF (1.00)
Anthracyclines-based	83	1.04 (0.79-1.38)	51	1.81 (1.22-2.70)	44	1.15 (0.78-1.68)
Anthracyclines +Taxanes	10	0.92 (0.47-1.79)	13	4.27 (2.18-8.35)	6	1.23 (0.51-2.94)
CMF	6	0.85 (0.37-1.95)	3	0.98 (0.30-3.17)	2	0.51 (0.13-2.11)
Type unknown	87	1.20 (0.89-1.61)	38	1.42 (0.91-2.21)	47	1.41 (0.95-2.10)
Missing	8		5		1	
Hormone therapy						
No	89	REF (1.00)	49	REF (1.00)	43	REF (1.00)
Tamoxifen	298	0.99 (0.76-1.27)	99	0.78 (0.54-1.12)	142	0.98 (0.68-1.42)
Aromatase inhibitors	119	1.06 (0.79-1.42)	61	1.03 (0.68-1.55)	85	1.48 (1.00-2.20)
Type unknown	56	0.91 (0.64-1.30)	29	0.91 (0.55-1.50)	36	1.17 (0.73-1.88)
Missing	8		5		1	
Trastuzumab *						
No	129	REF (1.00)	39	REF (1.00)	60	REF (1.00)
Yes	18	1.21 (0.71-2.04)	13	2.00 (1.02-3.92)	13	1.57 (0.82-2.99)
Missing	93		39		52	

Abbreviations: Total No. refers to the total number of patients. N events refers to the number of observed cases. HR = hazard ratio; CI = confidence interval. Hazard ratios are estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios are multivariable adjusted including age at diagnosis (years), year of diagnosis (2001/2002, 2003/2004, 2005/2006, 2007/2008), menopausal status (premenopausal, postmenopausal, unknown), Charlson comorbidity index (0, 1, \geq 2), clinical stage (I, II, III, unknown), type of surgery (no, partial mastectomy, total mastectomy, unknown), and all treatment variables listed in the table. * Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

618

Regional Breast Cancer cohort	7		sponding General Population
Patients living in the Stockholm /Gotland region during 2001-2008 <i>n</i> =10,007			en living in Stockholm/Gotland g 2001-2017 9,183
Women diagnosed with primary invasive breast cancer (Follow up to Dec 31, 2017) Age= 25-75 n = 8,658		Matched cohort on year of birth ar history of arrhythmia (Follow up to 31, 2017) Age= 25-75 <i>n</i> =83,365	
Women diagnosed with primary invasive stage I-III breast cancer (Follow up to Dec 31, 2017) Age= 25-75 n = 8,338	×>	Matched cohort on year of birth ar history of ischemic heart disease (F up to Dec 31, 2017) Age= 25-75 n=83,363	
		Matched cohort on year of birth a history of heart failure (Follow up 31, 2017) Age= 25-75 n=83,368	

656 Supplementary Figure 2. Cumulative incidence of heart diseases in breast cancer patients and matched reference individuals from the general

657 population.

